Published in EMBO J on October 15, 2009
TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer (2010) 5.27
TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst (2014) 2.08
Resistance to discodermolide, a microtubule-stabilizing agent and senescence inducer, is 4E-BP1-dependent. Proc Natl Acad Sci U S A (2010) 0.86
Transforming Growth Factor-β1 Induced Epithelial Mesenchymal Transition is blocked by a chemical antagonist of translation factor eIF4E. Sci Rep (2015) 0.86
Eukaryotic Translation Initiation Factor 4E Is a Feed-Forward Translational Coactivator of Transforming Growth Factor β Early Protransforming Events in Breast Epithelial Cells. Mol Cell Biol (2015) 0.81
Expression of eukaryotic initiation factor 4E and 4E binding protein 1 in colorectal carcinogenesis. Int J Clin Exp Pathol (2015) 0.80
Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors. Sci Signal (2015) 0.78
Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression. Carcinogenesis (2015) 0.77
Total 4EBP1 Is Elevated in Liver of Rats in Response to Low Sulfur Amino Acid Intake. J Amino Acids (2013) 0.77
BxPC3 pancreatic cancer cells express a truncated Smad4 protein upon PI3K and mTOR inhibition. Oncol Lett (2014) 0.77
Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro. Oncotarget (2017) 0.75
eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem (1999) 14.59
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 11.13
Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer (2003) 8.35
Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature (2005) 6.69
Molecular mechanisms of translational control. Nat Rev Mol Cell Biol (2004) 6.39
New insights into TGF-beta-Smad signalling. Trends Biochem Sci (2004) 6.13
eIF-4E expression and its role in malignancies and metastases. Oncogene (2004) 5.10
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
eIF4E--from translation to transformation. Oncogene (2004) 3.78
Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol Cell Biol (1999) 3.55
Dissecting eIF4E action in tumorigenesis. Genes Dev (2007) 3.53
Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell (2004) 2.91
A cell cycle-dependent internal ribosome entry site. Mol Cell (2000) 2.91
Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest (2007) 2.86
4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res (2007) 2.67
Suppression of cap-dependent translation in mitosis. Genes Dev (2001) 2.11
Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell (2004) 1.91
Starvation and oxidative stress resistance in Drosophila are mediated through the eIF4E-binding protein, d4E-BP. Genes Dev (2005) 1.84
ATF4-mediated induction of 4E-BP1 contributes to pancreatic beta cell survival under endoplasmic reticulum stress. Cell Metab (2008) 1.62
Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. Exp Cell Res (2005) 1.53
Regulation of Smad activities. Biochim Biophys Acta (2006) 1.41
Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res (1997) 1.34
Transforming growth factor-beta 1 inhibits cyclin D1 expression in intestinal epithelial cells. Oncogene (1995) 1.24
TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation. Oncogene (2000) 1.14
Transforming growth factor-beta requires its target plasminogen activator inhibitor-1 for cytostatic activity. J Biol Chem (2008) 1.09
A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis. Oncogene (2004) 1.00
Restoration of functional gap junctions through internal ribosome entry site-dependent synthesis of endogenous connexins in density-inhibited cancer cells. Mol Cell Biol (2005) 1.00
HMGA1 controls transcription of insulin receptor to regulate cyclin D1 translation in pancreatic cancer cells. Cancer Res (2007) 0.97
Tissue distribution, genomic structure, and chromosome mapping of mouse and human eukaryotic initiation factor 4E-binding proteins 1 and 2. Genomics (1996) 0.95
Phosphatidylinositol 3-kinase-dependent transcriptional silencing of the translational repressor 4E-BP1. Cell Mol Life Sci (2008) 0.94
eIF4E association with 4E-BP decreases rapidly following fertilization in sea urchin. Dev Biol (2001) 0.94
Signal transduction. Protein synthesis and oncogenesis meet again. Science (2006) 0.92
Transcriptional activation of mouse sst2 somatostatin receptor promoter by transforming growth factor-beta. Involvement of Smad4. J Biol Chem (2001) 0.84
Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J (2006) 2.41
Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multi-center French study. Cancer Biol Ther (2009) 1.40
Antitumor effects of somatostatin. Mol Cell Endocrinol (2008) 1.30
Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther (2009) 1.30
Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci U S A (2002) 1.23
Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells. Gastroenterology (2010) 1.22
Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol (2008) 1.15
Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol (2005) 1.11
Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. EMBO J (2006) 1.11
Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res (2002) 1.10
Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy. J Clin Endocrinol Metab (2011) 1.10
Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples. World J Gastroenterol (2006) 1.09
The rat tyrosine phosphatase eta increases cell adhesion by activating c-Src through dephosphorylation of its inhibitory phosphotyrosine residue. Oncogene (2005) 1.08
Molecular signaling of somatostatin receptors. Ann N Y Acad Sci (2004) 1.06
Restoration of functional gap junctions through internal ribosome entry site-dependent synthesis of endogenous connexins in density-inhibited cancer cells. Mol Cell Biol (2005) 1.00
Control of Paip1-eukayrotic translation initiation factor 3 interaction by amino acids through S6 kinase. Mol Cell Biol (2014) 0.99
sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem (2003) 0.95
Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proc Natl Acad Sci U S A (2009) 0.95
Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications. Endocrinology (2008) 0.92
Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation. Mol Biol Cell (2003) 0.92
The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways. PLoS One (2012) 0.91
Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. Mol Ther (2006) 0.91
Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. J Clin Endocrinol Metab (2002) 0.90
A novel protein-protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin-induced inhibition of cell proliferation. J Biol Chem (2002) 0.90
Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. Hum Gene Ther (2005) 0.90
Cap-dependent translation and control of the cell cycle. Prog Cell Cycle Res (2003) 0.88
Juvenile hormone binding protein traffic -- Interaction with ATP synthase and lipid transfer proteins. Biochim Biophys Acta (2009) 0.86
Overexpression of high molecular weight FGF-2 forms inhibits glioma growth by acting on cell-cycle progression and protein translation. Exp Cell Res (2008) 0.85
eIF4E/4E-BP dissociation and 4E-BP degradation in the first mitotic division of the sea urchin embryo. Dev Biol (2003) 0.85
A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85 to filamin A negatively controls the PI3K pathway. Mol Cell Biol (2011) 0.84
Fibroblast growth factor 1 induced during myogenesis by a transcription-translation coupling mechanism. Nucleic Acids Res (2009) 0.84
NAD(P)H quinone-oxydoreductase 1 protects eukaryotic translation initiation factor 4GI from degradation by the proteasome. Mol Cell Biol (2009) 0.84
Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects. Best Pract Res Clin Gastroenterol (2005) 0.84
Control of contact-inhibition by 4E-BP1 upregulation. Cell Cycle (2010) 0.83
High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor. Oncogene (2003) 0.83
PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen. Mod Pathol (2003) 0.83
Inhibitory role of the somatostatin receptor SST2 on the intracrine-regulated cell proliferation induced by the 210-amino acid fibroblast growth factor-2 isoform: implication of JAK2. J Biol Chem (2003) 0.83
c-Jun NH(2)-terminal kinase pathway in growth-promoting effect of the G protein-coupled receptor cholecystokinin B receptor: a protein kinase C/Src-dependent-mechanism. Cell Growth Differ (2002) 0.81
Contribution of HIF-1α in 4E-BP1 gene expression. Mol Cancer Res (2012) 0.81
Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. J Clin Invest (2016) 0.80
An intracellular multi-effector complex mediates somatostatin receptor 1 activation of phospho-tyrosine phosphatase eta. Mol Endocrinol (2006) 0.79
Regulation of neuronal nitric-oxide synthase activity by somatostatin analogs following SST5 somatostatin receptor activation. J Biol Chem (2006) 0.79
Identification of c-Jun as a critical mediator for the intracrine 24 kDa FGF-2 isoform-induced cell proliferation. Int J Cancer (2005) 0.78
Transfection of pancreatic-derived beta-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion. Endocrinology (2002) 0.77
Changes in translational control after pro-apoptotic stress. Int J Mol Sci (2012) 0.77
EZH2 links pancreatitis to tissue regeneration and pancreatic cancer. Clin Res Hepatol Gastroenterol (2012) 0.76
Inflammation triggers and sustains a pathological threshold of Ras activity necessary to induce pancreatic tumorigenesis. Clin Res Hepatol Gastroenterol (2012) 0.75